Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
A Study of Avastin (Bevacizumab) in Women with HER2 Negative Metastatic Breast Cancer
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination with Chemotherapy in Patients with Primary breast Cancer
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: IV
ATHENA Study: A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: III
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) plus Herceptin (Trastuzumab) in Patients WIth Primary Inflammatory HER2-Positive Breast Cancer.
Product Name: Epothilone D
Date of Report: To be Published
Phase: II
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Product Name: Epothilone D
Date of Report: To be Published
Phase: II
A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.
Product Name: Herceptin [trastuzumab]
Date of Report: 10/11/2002
Phase: IV
Expanded access programme: treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer (MBC) who overexpress HER2
Product Name: Herceptin [trastuzumab]
Date of Report: 9/15/2003
Phase: II
A Multicenter, Randomized Comparative Study on the Efficacy and Safety of Herceptin (Trastuzumab) Plus Docetaxel (Taxotere) Versus Docetaxel Alone as First Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: 1/1/2004
Phase: II
A multicenter, open-label, single arm phase II study of safety and efficacy of a three-weekly regimen of Herceptin monotherapy in patients with HER2-overexpressing/amplification in metastatic breast cancer.
Product Name: Herceptin [trastuzumab]
Date of Report: 3/11/2004
Phase: II
Trastuzumab (Ro 45-2317) in combination with epirubicin and docetaxel as first-line chemotherapy in metastatic breast cancer patients
Product Name: Herceptin [trastuzumab]
Date of Report: 9/1/2004
Phase: II
Pharmacokinetic Study of Herceptin® (H) and Doxorubicin (A) plus Paclitaxel (T) followed by weekly Paclitaxel (AT+/-H→TH) in Women with Metastatic Breast Cancer and HER2 Overexpression.
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: II
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: IV
A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: II
A Study of Herceptin (Trastuzumab) in Women With c-erbB2–Positive Metastatic Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: III
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: II
A Study of Herceptin (Trastuzumab) in Combination Therapy in Patients with Metastatic Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: III
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients with Advanced Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: 10/3/2005
Phase: II
An open label randomised phase 2 study of trastuzumab (Herceptin) given with weekly paclitaxel (Taxol) versus weekly paclitaxel as single agent in first-line therapy for patients with HER-2/neu overexpressing advanced breast cancer (ABC).
Product Name: Herceptin [trastuzumab]
Date of Report: 1/1/2006
Phase: III
A randomized three-arm multi-center comparison of 1 year and 2 years of Herceptin® versus no Herceptin® in women with HER2-positive primary breast cancer who have completed adjuvant therapy.
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: II
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer
Product Name: Herceptin [trastuzumab]
Date of Report: 7/3/2006
Phase: II
A phase II trial evaluating the administration of trastuzumab in combination with cisplatin-epirubicin-paclitaxel (PETH) in metastatic breast cancer patients.
Product Name: Herceptin [trastuzumab]
Date of Report: 8/1/2006
Phase: III
A randomized, controlled, open-label study to evaluate the efficacy and safety of Herceptin® (trastuzumab) in combination with the oral aromatase inhibitor Arimidex® compared with Arimidex® alone as first line (and second line hormonal) treatment administered to post menopausal, hormone receptor positive (ER+ and/or PgR+) patients with HER2 overexpressing metastatic breast cancer.
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: III
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Product Name: Herceptin [trastuzumab]
Date of Report: To be Published
Phase: III
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Product Name: Herceptin [trastuzumab]
Date of Report: 4/1/2008
Phase: IV
A phase I/II study of a loading regimen (6mg/kg weekly for 3 weeks) followed by maintenance regimen (6mg/kg every 3 weeks), of Herceptin monotherapy in women with HER2 positive metastatic breast cancer.
Product Name: Herceptin [trastuzumab]
Date of Report: 4/1/2008
Phase: II
An open-label, randomized phase II study of Herceptin (trastuzumab), Taxotere (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (trastuzumab) plus Taxotere (docetaxel), in patients with advanced and/or metastatic breast cancers that overexpress HER2.
Product Name: Neulastim [pegfilgrastim]
Date of Report: To be Published
Phase: IV
An Expanded Access Program of Neulastim (Pegfilgrastim) in Patients With Breast Cancer.
Product Name: pertuzumab
Date of Report: 11/1/2005
Phase: II
Open label, phase II, multicenter, randomized study of efficacy and safety for two different doses of a recombinant humanized antibody to HER2 (rhuMAb 2C4) administered every 3 weeks to patients with metastatic breast cancer with low expression of HER2.
Product Name: pertuzumab
Date of Report: To be Published
Phase: II
A Study of Pertuzumab in Combination with Herceptin in Patients with Metastatic Breast Cancer
Product Name: pertuzumab
Date of Report: To be Published
Phase: II
A Study of Pertuzumab in Combination with Herceptin in Patients With HER2 Positive Breast Cancer.
Product Name: pertuzumab
Date of Report: To be Published
Phase: III
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Product Name: Tarceva [erlotinib]
Date of Report: To be Published
Phase: II
A Dose-Finding Study of Tarceva (Erlotinib) Given After Vinorelbine and Xeloda in Patients With Metatstatic Breast Cancer.
Product Name: Xeloda [capecitabine]
Date of Report: 3/2/2001
Phase: III
An Open-Label Randomized Phase III Study of Capecitabine in Combination with Docetaxel (Taxotere) Versus Docetaxel Monotherapy in Patients with Advanced and/or Metastatic Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: 4/23/2003
Phase: II
A Phase 2 study on the use of capecitabine in patients ≥65 years with advanced breast cancer
Product Name: Xeloda [capecitabine]
Date of Report: 5/10/2004
Phase: IV
A Phase II study of capecitabine (Ro 09-1978) in patients with metastatic breast cancer, who relapsed after treatment with a taxane-containing chemotherapy.
Product Name: Xeloda [capecitabine]
Date of Report: 10/1/2004
Phase: II
Phase I/II study of the combination capecitabine and vinorelbine as chemotherapy for metastatic breast cancer.
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: III
A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: III
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: IV
XeNA study A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: II
A Study of Xeloda (Capecitabine) in Patients With Metastatic or Locally Advanced Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: II
A Study of Xeloda (Capecitabine) Prior to Surgery in Women With Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: IV
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Product Name: Xeloda [capecitabine]
Date of Report: 10/26/2005
Phase: IV
An open-label, randomized, phase III study of capecitabine in combination with docetaxel vs capecitabine followed by docetaxel as first-line treatment for metastatic breast cancer
Product Name: Xeloda [capecitabine]
Date of Report: 11/21/2006
Phase: II
An open-label phase II study of intermittent oral capecitabine in combination with docetaxel (q3w) in patients with advanced and/or metastatic breast cancer.
Product Name: Xeloda [capecitabine]
Date of Report: 6/15/2007
Phase: III
A phase III study comparing taxotere, epirubicin and Xeloda (TEX) versus epirubicin and taxotere (ET) in advanced breast cancer patients.
Product Name: Xeloda [capecitabine]
Date of Report: To be Published
Phase: III
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated WIth Oral Xeloda (Capecitabine).
